GSK plc vs T-Mobile Us Inc — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while T-Mobile Us Inc trades at $148.88 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 2× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and T-Mobile Us Inc for 84 Days on average.
| GSK | TMUS | |
|---|---|---|
Market Cap | $91.88B | $183.76B |
Volume | 7,730,529 | 4,294,650 |
Sector | Health | Media |
52-Week High | $61.18 | $230.06 |
52-Week Low | $43.24 | $161.73 |
Typical Hold Time | 93 Days | 84 Days |
Enterprise Value | $111.88B | $300.37B |
Dividend Yield | 3.9% | 2.73% |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
T-Mobile US (TMUS) trades at $148.58, down 11.36% over 24 hours, reflecting recent market pressure. The stock shows strong fundamental health with revenue growth to $88.31B in 2025 and a net income margin of 11.45%. Analyst consensus is strongly bullish with a $231.10 price target, supported by a 15% dividend hike announced in September 2026. Technical indicators are mixed, with a bearish moving average signal but neutral oscillators, while recent news highlights AI-driven 5G advancements and a joint venture with AT&T and Verizon to expand coverage.
The outlook for TMUS is positive due to robust earnings beats, strategic initiatives, and solid cash flow, though risks include high debt levels and competitive pressures. Investors may find value in its growth trajectory and dividend increases, but should monitor debt management and industry competition closely.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →